Literature DB >> 28379375

Clinical, Serological, and Virological Analysis of 572 Chikungunya Patients From 2010 to 2013 in India.

Jaspreet Jain1, Kaustuv Nayak2, Neha Tanwar3, Rajni Gaind3, Bhupendra Gupta4, J S Shastri5, Raj K Bhatnagar6, Murali Krishna Kaja2,7, Anmol Chandele2, Sujatha Sunil1.   

Abstract

Background: Chikungunya fever (CHIK) is a major public health concern in India. Characterized by acute fever with joint pain and swelling, most patients recover from this self-limiting illness in 7-10 days, with cessation of joint pain post-acute episode. However, in some patients, joint pain persists, lasting for months or even years. The precise correlates to the chronic phase of this debilitating illness and/or this remarkable heterogeneity in disease manifestation are poorly understood.
Methods: We evaluated 572 chikungunya patients from India who were recruited on the basis of positive real-time polymerase chain reaction and/or CHIK virus immunoglobulin (IgM) after receiving consent. Arthralgic conditions were monitored using visual analog score (VAS) 12 weeks after onset of fever in 130 patients. Initial viral load, IgG, and initial neutralization response were assayed and correlated with clinical and VAS information in 40 patients.
Results: Our extensive screening revealed that patients with higher initial viral loads during the acute phase of illness had poor prognosis at the post-acute phase with more restricted joint movement and higher VAS. Additionally, patients who showed early seroconversion to neutralizing IgG responses had better prognosis, as many of these patients did not manifest restricted joint movements at the post-acute phase. Conclusions: Our study sheds light on chikungunya disease with respect to disease progression and assesses clinical, virological, and serological parameters of chikungunya disease severity. Importantly, it reveals that initial high viral load and neutralizing IgG response may function in a seemingly contrasting manner to negatively or positively dictate disease outcome.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Chikungunya; India; neutralizing antibodies; viral load

Mesh:

Substances:

Year:  2017        PMID: 28379375     DOI: 10.1093/cid/cix283

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

1.  Chikungunya-specific IgG and neutralizing antibody responses in natural infection of Chikungunya virus in children from India.

Authors:  Anil Verma; Kaustuv Nayak; Anmol Chandele; Mohit Singla; Vinod H Ratageri; Rakesh Lodha; Sushil Kumar Kabra; Kaja Murali-Krishna; Pratima Ray
Journal:  Arch Virol       Date:  2021-04-27       Impact factor: 2.574

Review 2.  Beyond Fever and Pain: Diagnostic Methods for Chikungunya Virus.

Authors:  Muktha S Natrajan; Alejandra Rojas; Jesse J Waggoner
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

3.  Interferon Alpha, but Not Interferon Beta, Acts Early To Control Chronic Chikungunya Virus Pathogenesis.

Authors:  Marissa C Locke; Lindsey E Fox; Bria F Dunlap; Alissa R Young; Kristen Monte; Deborah J Lenschow
Journal:  J Virol       Date:  2021-10-20       Impact factor: 6.549

4.  Chikungunya Outbreaks in India: A Prospective Study Comparing Neutralization and Sequelae during Two Outbreaks in 2010 and 2016.

Authors:  Jaspreet Jain; Navjot Kaur; Sherry L Haller; Ankit Kumar; Shannan L Rossi; Vimal Narayanan; Dilip Kumar; Rajni Gaind; Scott C Weaver; Albert J Auguste; Sujatha Sunil
Journal:  Am J Trop Med Hyg       Date:  2020-04       Impact factor: 2.345

5.  Antibody response patterns in chikungunya febrile phase predict protection versus progression to chronic arthritis.

Authors:  Kaustuv Nayak; Vineet Jain; Manpreet Kaur; Naushad Khan; Kamalvishnu Gottimukkala; Charu Aggarwal; Rohit Sagar; Shipra Gupta; Ramesh Chandra Rai; Kritika Dixit; Mohammad Islamuddin; Wajihul Hasan Khan; Anil Verma; Deepti Maheshwari; Yadya M Chawla; Elluri Seetharami Reddy; Harekrushna Panda; Pragati Sharma; Priya Bhatnagar; Prabhat Singh; Siva Raghavendhar B; Ashok Kumar Patel; Vinod H Ratageri; Anmol Chandele; Pratima Ray; Kaja Murali-Krishna
Journal:  JCI Insight       Date:  2020-04-09

6.  Chikungunya virus infection in Aruba: Diagnosis, clinical features and predictors of post-chikungunya chronic polyarthralgia.

Authors:  Ralph Huits; Jaclyn De Kort; Riemsdijk Van Den Berg; Luis Chong; Achilleas Tsoumanis; Kaat Eggermont; Koen Bartholomeeusen; Kevin K Ariën; Jan Jacobs; Marjan Van Esbroeck; Emmanuel Bottieau; Lieselotte Cnops
Journal:  PLoS One       Date:  2018-04-30       Impact factor: 3.240

7.  In silico analysis of natural compounds targeting structural and nonstructural proteins of chikungunya virus.

Authors:  Jaspreet Jain; Anchala Kumari; Pallavi Somvanshi; Abhinav Grover; Somnath Pai; Sujatha Sunil
Journal:  F1000Res       Date:  2017-08-30

8.  In Vivo Evaluation of Withania somnifera-Based Indian Traditional Formulation ( Amukkara Choornam), Against Chikungunya Virus-Induced Morbidity and Arthralgia.

Authors:  Jaspreet Jain; Vimal Narayanan; Shivam Chaturvedi; Somnath Pai; Sujatha Sunil
Journal:  J Evid Based Integr Med       Date:  2018 Jan-Dec

9.  Evaluation of an immunochromatography rapid diagnosis kit for detection of chikungunya virus antigen in India, a dengue-endemic country.

Authors:  Jaspreet Jain; Tamaki Okabayashi; Navjot Kaur; Emi Nakayama; Tatsuo Shioda; Rajni Gaind; Takeshi Kurosu; Sujatha Sunil
Journal:  Virol J       Date:  2018-05-11       Impact factor: 4.099

Review 10.  Mother-to-child transmission of Chikungunya virus: A systematic review and meta-analysis.

Authors:  Despina Contopoulos-Ioannidis; Shoshana Newman-Lindsay; Camille Chow; A Desiree LaBeaud
Journal:  PLoS Negl Trop Dis       Date:  2018-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.